Displaying 181 - 200 of 853
| Active Ingredient | TOCILIZUMAB |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | TOFACITINIB |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | TRASTUZUMAB |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | VINBLASTINE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Hodgkins disease, lympomas. |
| Caution | Nausea and vomiting, stomatitis, constipation or diarrhoea, leukopenia. |
| Dose Range | 6 mg/m2, not more often than once every 7 days. Maximum dose 11.1 mg/m2. |
| Drug Interactions | |
| Pregnancy | Vinblastine is not recommended during pregnancy. |
| Breast Feeding | Breastfeeding is not recommended during therapy. |
| Active Ingredient | VINCRISTINE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Acute and chronic leukaemias, lymphomas. |
| Caution | Leukopenia, nausea and vomiting, stomach or diarrhoea, leukopenia. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | May cause fetal harm if administered during pregnancy. Women of child-bearing ag More ... |
| Breast Feeding | Breastfeeding is not recommended during therapy. |
| Active Ingredient | AUTONOMIC DRUGS |
| Therapeutic Class | AUTONOMIC DRUGS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | BETHANECHOL |
| Therapeutic Class | PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS |
| Indications | Urinary retention, post-operative dystension due to paralyticileus. |
| Caution | Take on empty stomach. May cause dizziness or drowsiness. See neostigmine. |
| Dose Range | Adult: 10-50mg 3-4 times daily . Inj. 5mg s.c. and repeat (double if necessary , according to individual response). |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DONEPEZIL |
| Therapeutic Class | PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS |
| Indications | Mild to moderate dementia in Alzheimer’s disease. |
| Caution | Nausea, diarrhea, fatigue, headache, dizziness, agitation, muscle cramps. |
| Dose Range |
Initially 5mg once daily at bedtime increased if necessary after 4-6 weeks to 10mg once daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | NEOSTIGMINE |
| Therapeutic Class | PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS |
| Indications | Treatment of myasthenia gravis but very short acting. (Half-life may be less than 1 hour). |
| Caution |
Prototype anticholinesterase, para-sympathomimetic. Nausea, vomiting, abdominal cramps, salivation, diarrhoea, sweating, miosis, brady cardia, hypotension, agitation and dreaming. Weakness with ove More ... |
| Dose Range | Adult: 15-60mg every 2-4 hours as necessary . 1-2.5mg i.m. in emergencies. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PYRIDOSTIGMINE |
| Therapeutic Class | PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS |
| Indications | Myasthenia gravis. Preferable to neostigmine because of longer half-life (1-3 hours). Delayed format is available. |
| Caution | As for neostigmine; note "Cholinergic Crises' or paralysis due to over medication (abdominal cramp s most useful warning). C.f. prescribing in renal disease p. 36. |
| Dose Range | Adult: 60-180mg every 3-6 hours, carefully titrated for optimal effects. Paediatric: under 6 y ears: 30 mg; 6 to 12 y ears: 60 mg, increasing to a maximum of 30 to 360 mg daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | Breastfeeding is not recommended during treatment with pyridostigmine. |
| Active Ingredient | RIVASTIGMINE |
| Therapeutic Class | PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ATROPINE SULPHATE |
| Therapeutic Class | ANTIMUSCARINICS/ANTISPASMODICS |
| Indications | Most commonly used premedication agent to dry bronchial and salivary secretions. Also drug of choice for immediate treatment of excessive bradycardia. |
| Caution | Glaucoma, dry mouth, paralyticileus, excessive tachycardia, urinary retention and constipation. |
| Dose Range |
i.v. 0.3 - 0.6mg immediately before induction of anaesthesia or reversal of brady cardia i.m. 0.3 - 0.6mg, repeat if necessary . |
| Drug Interactions | |
| Pregnancy | Use with caution. Atropine readily crosses the placenta. |
| Breast Feeding | May suppress lactation. |
| Active Ingredient | HYOSCINE BUTYLBROMIDE |
| Therapeutic Class | ANTIMUSCARINICS/ANTISPASMODICS |
| Indications | Aid in pepticulcer and spastic colon. |
| Caution | |
| Dose Range |
Adult: 10-20mg 2-4 times daily as necessary . Pediatric 6-12 years: 10mg 3 times daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | HYOSCINE BUTYLBROMIDE | PARACETAMOL |
| Therapeutic Class | ANTIMUSCARINICS/ANTISPASMODICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | TOLTERODINE |
| Therapeutic Class | ANTIMUSCARINICS/ANTISPASMODICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PHENYLEPHRINE |
| Therapeutic Class | ALPHA ADRENERGIC AGONIST |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DOBUTAMINE |
| Therapeutic Class | BETA ADRENERGIC AGONIST |
| Indications | Inotropic support in infarction, cardiac surgery, cardiomyopathies, septic shock, cardiogenic shock. |
| Caution | Dose-related increases in heart rate and blood pressure, ectopic beats, angina or chest pain, and palpitations; dosage should be reduced or temporarily stopped if they occur. |
| Dose Range | i.v. infusion: 2.5-10 micrograms/kg/minute, adjusted according to response, alternatively 0.5-40 micrograms/kg/minute. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DOPAMINE |
| Therapeutic Class | BETA ADRENERGIC AGONIST |
| Indications | Cardiogenic shock in myocardial infarction. |
| Caution | Correct hypovolemia, CVP monitoring advisable. Extravasation, may cause necrosis. Recommended that a large central vein be used for infusion. Nausea, peripheral vasoconstriction, tachy cardia. |
| Dose Range | i.v. infusion: 2-5mcg/kg/minute, increasing if necessary |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ISOPRENALINE |
| Therapeutic Class | BETA ADRENERGIC AGONIST |
| Indications | Sustained release preparation useful in patients with chronic sinus brady cardia, i.v. infusion for acute sinus brady cardia, heart block. |
| Caution | Tremor, tachy cardia, urinary retention; insomnia. Use with caution in heart disease. |
| Dose Range | Adult: i.v. infusion; 0.5-10mcg/minute. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ADRENALINE |
| Therapeutic Class | ALPHA & BETA ADRENERGIC AGONIST |
| Indications | Acute bronchospasm. Emergency treatment of asthma and anaphylaxis, cardiac arrest. |
| Caution | Cardiac arrhythmias, tachycardia, tremor, anxiety . Avoid in the elderly and patients with heart disease. |
| Dose Range | 0.5-1mg s.c. or i.m. |
| Drug Interactions | |
| Pregnancy | May reduce placental perfusion and cause tachycardia, cardiac irregularities, an More ... |
| Breast Feeding | Present in milk but unlikely to be harmful as poor oral bioavailability. |